Conference after conference, Roche scientists running the ongoing Brain Shuttle AD trial of trontinemab are dispensing ...

REAL AD hints that blood markers can spot subtle cognitive decline. People who fluff a digital cognitive test have more ...

Scientists see several important uses for staging. For example, it can steer people more precisely to appropriate treatments.

GBA1 mutations alone do not explain lysosomal dysfunction in PD. Loss of endosomal recycling proteins cripple this lysosomal enzyme. Without a protein called COMMD3, cells spit out would-be lysosomal ...

Tau PET correlates closely with cognitive decline in Alzheimer’s disease, making it a potential surrogate outcome measure. Yet in amyloid immunotherapy trials to date, this signal has not always ...

TREM2 created quite the buzz at this year’s AD/PD meeting, held April 1-5 in Vienna. In the wake of a TREM2 agonist’s demise, scientists presented optimistic findings from early phase trials of a ...

Some clinical trials for treatments that nip Alzheimer’s disease in the bud rely on recruiting carriers of autosomal-dominant mutations who will develop Alzheimer’s disease in a predictable fashion.

Single and multi-dose studies of the small molecule TREM2 agonist VG-3927 clear early safety hurdle. Meanwhile, new findings ...